Novel therapeutics in myeloproliferative neoplasms

Novel therapeutics in myeloproliferative neoplasms

Abstract Hyperactive signaling of the Janus-Associated Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) pathway is central to the pathogenesis of Philadelphia-chromosome-negative myeloproliferative neoplasms (MPN), i.e., polycythemia vera (PV), essential thrombocythemia (ET), and...

Bibliografski detalji
Glavni autori:	Sangeetha Venugopal, John Mascarenhas
Format:	Članak
Jezik:	English
Izdano:	BMC 2020-12-01
Serija:	Journal of Hematology & Oncology
Teme:	MF ET PV JAK-STAT CALR Ruxolitinib
Online pristup:	https://doi.org/10.1186/s13045-020-00995-y

Slični predmeti

Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms
od: Giuseppe Gaetano Loscocco, i dr.
Izdano: (2024-07-01)

The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis
od: Helna Pettersson, i dr.
Izdano: (2023-08-01)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
od: Bewersdorf JP, i dr.
Izdano: (2019-12-01)

The Role of New Technologies in Myeloproliferative Neoplasms
od: Giuseppe A. Palumbo, i dr.
Izdano: (2019-04-01)

Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
od: Li Huo, i dr.
Izdano: (2023-01-01)

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy
od: Sophia S. Lee, i dr.
Izdano: (2021-08-01)

Case Report: A Case of Myeloproliferative Neoplasm Complicated by Alopecia Areata
od: Yotaro Tamai, i dr.
Izdano: (2022-05-01)

The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up
od: Amina Kurtovic-Kozaric, i dr.
Izdano: (2020-05-01)

Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms
od: Ngo Tat Trung, i dr.
Izdano: (2019-06-01)

Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms
od: Velizar Shivarov, i dr.
Izdano: (2024-09-01)

Role of janus kinase inhibitors in the treatment of alopecia areata
od: Triyangkulsri K, i dr.
Izdano: (2018-07-01)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
od: Giuseppe G. Loscocco, i dr.
Izdano: (2021-08-01)

Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function
od: Iván Parra-Izquierdo, i dr.
Izdano: (2022-04-01)

Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms
od: Ken-Hong Lim, i dr.
Izdano: (2021-09-01)

Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms
od: Sivahari P. Gorantla, i dr.
Izdano: (2024-07-01)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
od: Camille Keenan, i dr.
Izdano: (2021-02-01)

Prevalence and clinicopathological features of driver gene mutations profile in BCR:ABL1 negative classical myeloproliferative neoplasm—A single-center study from North India
od: Khaliqur Rahman, i dr.
Izdano: (2024-12-01)

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review
od: Yingxin Sun, i dr.
Izdano: (2021-10-01)

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
od: Ana Micaela Carnaz Simões, i dr.
Izdano: (2022-05-01)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
od: Eylem Eliaçık, i dr.
Izdano: (2015-05-01)

Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia
od: Tobias Ronny Haage, i dr.
Izdano: (2024-06-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
od: Mohsen Razavi, i dr.
Izdano: (2011-10-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
od: Akram Asghari, i dr.
Izdano: (2011-12-01)

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
od: Ana Micaela Carnaz Simões, i dr.
Izdano: (2022-08-01)

JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients
od: Fanti Saktini, i dr.
Izdano: (2015-12-01)

Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker
od: Fadul A, i dr.
Izdano: (2024-12-01)

Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice
od: Keiji Minakawa, i dr.
Izdano: (2021-03-01)

Application of heteroduplex analysis for CALR mutation screening detection in patients with Ph-myeloproliferative neoplasms
od: T. N. Subbotina, i dr.
Izdano: (2021-06-01)

Arginase‐1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver
od: Arturo Bonometti, i dr.
Izdano: (2023-04-01)

JAK inhibitors to treat STAT3 gain-of-function: a single-center report and literature review
od: Faranaz Atschekzei, i dr.
Izdano: (2024-08-01)

Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway
od: Shin-Yi Chung, i dr.
Izdano: (2021-07-01)

Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit
od: Xilan Yang, i dr.
Izdano: (2020-03-01)

Remodeling the Bone Marrow Microenvironment – A Proposal for Targeting Pro-inflammatory Contributors in MPN
od: Jonas Samuel Jutzi, i dr.
Izdano: (2020-08-01)

Calreticulin Immunohistochemistry in Myeloproliferative Neoplasms - Evolution of a New Cost-Effective Diagnostic Tool: A Retrospective Study with Histological and Molecular Correlation
od: Sanjeet ROY, i dr.
Izdano: (2022-01-01)

Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review
od: Jona F. Houthuys, i dr.
Izdano: (2022-12-01)

Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients
od: Christopher Puli'uvea, i dr.
Izdano: (2024-12-01)

Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms
od: Tobias Idor Boklund, i dr.
Izdano: (2024-05-01)

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review
od: Mostafa Najim, i dr.
Izdano: (2024-12-01)

Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition
od: Hua Zhu, i dr.
Izdano: (2021-07-01)

MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment
od: Julian Grabek, i dr.
Izdano: (2020-08-01)